Armistice Capital’s Novo Nordisk NVO Stock Holding History

Armistice Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15M	Buy	+312,000	New	+$13.4M	0.18%	81
2026 Q1	–	Sell	-336,000	Closed	-$17.1M	–	408
2025 Q4	$17.1M	Sell	336,000 -400,000	-54%	-$20.5M	0.2%	78
2025 Q3	$40.8M	Buy	+736,000	New	+$43.1M	0.61%	25
2025 Q2	–	Sell	-108,000	Closed	-$7.5M	–	250
2025 Q1	$7.5M	Sell	108,000 -604,000	-85%	-$49.9M	0.11%	100
2024 Q4	$61.2M	Buy	712,000 +147,000	+26%	+$15.9M	0.84%	24
2024 Q3	$67.3M	Buy	565,000 +21,000	+4%	+$2.8M	1.08%	16
2024 Q2	$77.7M	Buy	544,000 +144,000	+36%	+$19.1M	0.98%	11
2024 Q1	$51.4M	Buy	400,000 +4,000	+1%	+$476K	0.68%	19
2023 Q4	$41M	Sell	396,000 -40,000	-9%	-$3.96M	0.56%	32
2023 Q3	$39.6M	Sell	436,000 -104,000	-19%	-$9.16M	0.61%	34
2023 Q2	$43.7M	Sell	540,000 -44,000	-8%	-$3.59M	0.63%	33
2023 Q1	$46.5M	Sell	584,000 -40,000	-6%	-$2.84M	0.67%	32
2022 Q4	$42.2M	Buy	+624,000	New	+$36.6M	0.74%	32

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Armistice Capital's NVO Position: Q2 2026 in Review

Armistice Capital opened a new position in Novo Nordisk (NVO) in Q2 2026: 312,000 shares worth $15M. The stake represents 0.18% of the portfolio and ranks #81 among its holdings. This is a return to the name: Armistice Capital previously reported a position in NVO as recently as Q4 2025.

Armistice Capital first reported a position in NVO in Q4 2022 and has held it in 13 quarters since. The position peaked at $77.7M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Armistice Capital held 312,000 shares of Novo Nordisk worth $15M as of Q2 2026.
Novo Nordisk was a new Armistice Capital position in Q2 2026.
Novo Nordisk made up 0.18% of Armistice Capital's portfolio in Q2 2026, its #81 holding.
Armistice Capital first reported a position in Novo Nordisk in Q4 2022 and has held it in 13 quarters since.
Armistice Capital's Novo Nordisk position peaked at $77.7M in Q2 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.